Consilium news

06 July 2023

Consilium Strategic Communications provides comprehensive support to MoonLake Immunotherapeutics on landmark clinical data and $400 million fundraise

London, 6 July 2023, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have provided investor relations and  strategic communications  advice to MoonLake Immunotherapeutics (Nasdaq:MLTX) (“MoonLake”) on key recent milestones including its positive Phase 2 trial results with sonelokimab, an investigational humanized Nanobody® designed to directly target sites of inflammation, and its subsequent $400 million financing.

On 25 June 2023, MoonLake announced positive data from its Phase 2 MIRA study investigating sonelokimab for hidradenitis suppurativa, a severely debilitating chronic skin condition resulting in irreversible tissue destruction. The MIRA study beat the best results observed in pivotal-like trials of competitors.

On 28 June 2023, MoonLake announced pricing of $400 million upsized public offering of Class A ordinary shares.  The funds raised, which shows the confidence and value investors see with the company, will enable MoonLake to advance sonelokimab toward registration, with the potential to be a multi-billion-dollar asset to address some of the fastest growing markets in inflammatory diseases.  

Mary-Jane Elliott, Founder and Managing Partner of Consilium Strategic Communications, commented: “Our team’s deep expertise and diverse skills have enabled us to provide comprehensive strategic communications and IR support to MoonLake at this critical time in its growth. We are proud to represent a company that has raised the bar for patients and is realising its ambition to become a leader in the inflammation and immunology space. We congratulate MoonLake on these achievements in a highly competitive and exciting area.” 

Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “We have worked closely with Consilium since November 2021 and have been impressed with the high level of senior support, the strategic communications advice and successful investor connectivity that the team has provided. The positive media and investor response we have received around our landmark data and public offering reflects the hard work and thorough preparation that Consilium, together with our team, put into supporting our communications around these major milestones.”

The Consilium team representing MoonLake is Mary-Jane Elliott, Matthew Cole, Chris Gardner, Ashley Tapp, Namrata Taak, Genevieve Wilson and Kumail Waljee. 

- ENDS -

For more information, please contact:

Consilium Strategic Communications

Mary-Jane Elliott / Amber Fennell

Tel: +44(0)20 3709 5700

info@consilium-comms.com

www.consilium-comms.com

Follow us: @consiliumhc

About Consilium Strategic Communications

Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.

For more information, please see www.consilium-comms.com